PTC THERAPEUTICS INC - NOTE 3.000% 8/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2016 to Q3 2022

Type / Class
Debt / NOTE 3.000% 8/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of PTC THERAPEUTICS INC - NOTE 3.000% 8/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2022 Q3 $0 $0 -$142,464,000 0
2022 Q2 $143,329,010 $144,470,360 -$18,634,748 100.79% 15
2022 Q1 $160,431,550 $165,092,000 +$26,167 101.76% 17
2021 Q4 $160,431,550 $170,264,000 -$7,501,556 105.26% 15
2021 Q3 $160,622,550 $174,058,000 -$2,043,659 104.46% 17
2021 Q2 $162,047,550 $181,591,000 +$5,573,381 107.81% 18
2021 Q1 $158,072,170 $187,694,000 -$2,974,721 115.17% 18
2020 Q4 $158,031,370 $212,822,000 +$490,292 128.83% 17
2020 Q3 $158,031,370 $187,728,000 +$15,984,564 113.52% 18
2020 Q2 $144,709,490 $172,327,641 +$5,014,850 116.09% 17
2020 Q1 $148,510,640 $163,074,555 +$7,291,075 111.7% 13
2019 Q4 $140,164,000 $161,344,000 +$8,930,623 115.31% 12
2019 Q3 $135,886,482 $149,480,000 -$12,783,716 103.97% 17
2019 Q2 $155,080,000 $171,687,336 -$1,386,012 110.8% 18
2019 Q1 $157,102,000 $162,565,487 +$5,268,861 103.6% 13
2018 Q4 $153,009,000 $151,517,153 -$6,408,158 99.4% 12
2018 Q3 $152,709,000 $176,238,003 +$11,573,569 115.22% 13
2018 Q2 $143,729,000 $142,648,487 -$3,922,037 98.88% 15
2018 Q1 $147,689,000 $137,090,707 +$24,337,406 93.16% 13
2017 Q4 $121,843,000 $95,574,792 -$584,460 77.4% 12
2017 Q3 $77,020,000 $62,074,960 +$1,318,555 80.36% 14
2017 Q2 $75,240,000 $58,689,372 +$853,206 77.47% 8
2017 Q1 $111,321,000 $70,763,632 -$1,940,940 63.56% 10
2016 Q4 $115,351,000 $69,665,000 -$13,041,824 59.56% 11
2016 Q3 $137,197,000 $75,791,000 +$75,791,000 56.13% 14